Canadian Neuromuscular Disease Registry Launches New Congenital Myasthenic Syndrome Registry

We’re delighted to announce that a new registry for patients with congenital myasthenic syndrome (CMS) has just been launched within the Canadian Neuromuscular Disease Registry (CNDR).  This new initiative is led by Dr. Hanns Lochmüller as an academic study as a part of Dr. Lochmüller’s CIHR foundation grant for CMS research, and supported by the NMD4C.

CMS are a diverse group of disorders that have an underlying defect in the transmission of signals from nerve cells to muscles. These disorders are characterized by muscle weakness that is worsened upon exertion[1]. The prevalence of CMS in populations under 18 years was measured to be between 2.8 and 14.8 per million children in a UK-based prevalence study[2]. This situates CMS as one of the rarer neuromuscular conditions, and there are over 30 different genes that may be involved.

By registering all patients across Canada, including those who have the clinical hallmarks of CMS but don’t yet have a genetic diagnosis, the aim of this registry is to improve access to diagnosis and treatment and develop a Canadian CMS cohort for future research. Individuals living with CMS can self-register directly with the CNDR or can register in-clinic if their local clinic is affiliated with the CNDR. Clinical centres that are already affiliated can activate the CMS module by going through a minor amendment with their REB – please contact Adrienna Dyck of the CNDR at to find out how to find out how. Since CMS is so rare, every new registration makes a difference!

The CNDR is a Canada-wide registry of people diagnosed with a neuromuscular disease, collecting important medical information from patients across the country to improve the understanding of neuromuscular disease and accelerate the development of new therapies. Currently, over 4500 neuromuscular patients have registered from across Canada. The new CMS registry is the latest addition to the CNDR’s current registries, which include Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy (DM), Spinal Muscular Atrophy (SMA). The CNDR also collects information on other NMDs.

The network would like to give special recognition the CNDR’s Dr. Victoria Hodgkinson and Adrienna Dyck, and the Lochmüller Lab’s Dr. Rachel Thompson for their contributions to the CMS registry project, as well as members of the expert group who helped refine the dataset: Drs. Lawrence Korngut, Kathy Selby, Craig Campbell, Hugh McMillan, Nicolas Chrestian, and Dr. Hanns Lochmüller.


[1] NORD (National Organization for Rare Disorders). 2022. Congenital Myasthenic Syndromes – NORD (National Organization for Rare Disorders). [online] Available at: <https://rarediseases.org/rare-diseases/congenital-myasthenic-syndromes/> [Accessed 24 February 2022].

[2] Parr, J., Andrew, M., Finnis, M., Beeson, D., Vincent, A. and Jayawant, S., 2014. How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Archives of Disease in Childhood, 99(6), pp.539-542.

CNDR_logo-2x3

Read next...

Ottawa NMD conference poster

Important Deadlines for Ottawa NMD 2023

The Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023) deadline for discounted early-bird registration and abstract submission is June 30th! 

ENMC mid-career mentoring programme

European Neuromuscular Centre Mid-Career Mentoring Programme Now Open

The European Neuromuscular Centre (ENMC) Mid-Career Mentoring Programme is now open for the third round of mentee candidates!

MNI logo

$6 million Brain Canada grant awarded to McGill to develop virtual integrated patient platform

NMD4C are pleased to share that The Neuro has received a $6 million grant from Brain Canada to fund a new Open Science patient registry to share data with researchers around the world and let patients see how their data is used to develop new treatments for neurological disorders.

xr:d:DAFhueqzCxw:6,j:3799255692,t:23050201

CIHR Report: What we heard on the future of clinical trials

The Canadian Institute of Health Research (CIHR) have recently released an article outlining the results of their building the future of clinical trials consultation in a What We Heard report.

NBS-2023

New Publication from NMD4C Investigators: Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond

A new study ‘Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond’ examines the differences between provincial newborn screening (NBS) programs and the variability of Spinal muscular atrophy (SMA) screening inclusion within these.

Muscular Dystrophy Canada have announced the nine projects funded through their 2023 research grants competition.

Muscular Dystrophy Canada fund nine new projects through 2023 grant program

Muscular Dystrophy Canada (MDC) recently announced the results of their ‘Neuromuscular Clinical and Translational Research Grant Program’, and we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting projects!